Skip to main content

Transplants and Implants

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
Enteric coated mycophenolate sodiumPhase 41 trial
Active Trials
NCT00522548Terminated37Est. Jan 2011
Cochlear
CochlearAustralia - Macquarie Park
1 program
N6N/A1 trial
Active Trials
NCT01800929Unknown30Est. Jun 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozEnteric coated mycophenolate sodium
CochlearN6

Clinical Trials (2)

Total enrollment: 67 patients across 2 trials

NCT00522548SandozEnteric coated mycophenolate sodium

Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients

Start: Mar 2007Est. completion: Jan 201137 patients
Phase 4Terminated

Evaluation of Performance and Usability of N6 in the Paediatric Population

Start: Nov 2012Est. completion: Jun 201330 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.